View in EDS

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.

Saved in:
Bibliographic Details
Title: A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
Authors: Cherng HJ; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY., Alig SK; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA., Oki Y; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Nastoupil LJ; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Fayad L; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Neelapu SS; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Turturro F; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Hagemeister F; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Craig AFM; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA., Macaulay CW; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA., Rodriguez MA; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee HJ; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., McDonnell TJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Flowers CR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Vega F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Green MR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Kurtz DM; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA., Alizadeh AA; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA., Davis RE; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Westin JR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Source: Blood advances [Blood Adv] 2023 Apr 11; Vol. 7 (7), pp. 1137-1145.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36375046
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cherng+HJ%22">Cherng HJ</searchLink>; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Alig+SK%22">Alig SK</searchLink>; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Oki+Y%22">Oki Y</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Nastoupil+LJ%22">Nastoupil LJ</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Fayad+L%22">Fayad L</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Neelapu+SS%22">Neelapu SS</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Turturro+F%22">Turturro F</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Hagemeister+F%22">Hagemeister F</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Craig+AFM%22">Craig AFM</searchLink>; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Macaulay+CW%22">Macaulay CW</searchLink>; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Rodriguez+MA%22">Rodriguez MA</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Lee+HJ%22">Lee HJ</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22McDonnell+TJ%22">McDonnell TJ</searchLink>; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Flowers+CR%22">Flowers CR</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Vega+F%22">Vega F</searchLink>; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Green+MR%22">Green MR</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Feng+L%22">Feng L</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Kurtz+DM%22">Kurtz DM</searchLink>; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Alizadeh+AA%22">Alizadeh AA</searchLink>; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Davis+RE%22">Davis RE</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Westin+JR%22">Westin JR</searchLink>; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2023 Apr 11; Vol. 7 (7), pp. 1137-1145.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36375046
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2022008174
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1137
    Titles:
      – TitleFull: A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cherng HJ
      – PersonEntity:
          Name:
            NameFull: Alig SK
      – PersonEntity:
          Name:
            NameFull: Oki Y
      – PersonEntity:
          Name:
            NameFull: Nastoupil LJ
      – PersonEntity:
          Name:
            NameFull: Fayad L
      – PersonEntity:
          Name:
            NameFull: Neelapu SS
      – PersonEntity:
          Name:
            NameFull: Turturro F
      – PersonEntity:
          Name:
            NameFull: Hagemeister F
      – PersonEntity:
          Name:
            NameFull: Craig AFM
      – PersonEntity:
          Name:
            NameFull: Macaulay CW
      – PersonEntity:
          Name:
            NameFull: Rodriguez MA
      – PersonEntity:
          Name:
            NameFull: Lee HJ
      – PersonEntity:
          Name:
            NameFull: McDonnell TJ
      – PersonEntity:
          Name:
            NameFull: Flowers CR
      – PersonEntity:
          Name:
            NameFull: Vega F
      – PersonEntity:
          Name:
            NameFull: Green MR
      – PersonEntity:
          Name:
            NameFull: Feng L
      – PersonEntity:
          Name:
            NameFull: Kurtz DM
      – PersonEntity:
          Name:
            NameFull: Alizadeh AA
      – PersonEntity:
          Name:
            NameFull: Davis RE
      – PersonEntity:
          Name:
            NameFull: Westin JR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 04
              Text: 2023 Apr 11
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1